Provided by Tiger Trade Technology Pte. Ltd.

Kura Oncology

8.26
-0.1700-2.02%
Volume:2.70M
Turnover:22.36M
Market Cap:729.60M
PE:-2.60
High:8.60
Open:8.43
Low:8.17
Close:8.43
52wk High:12.49
52wk Low:5.41
Shares:88.33M
Float Shares:63.99M
Volume Ratio:2.80
T/O Rate:4.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1784
EPS(LYR):-3.1784
ROE:-94.82%
ROA:-25.33%
PB:4.19
PE(LYR):-2.60

Loading ...

Kura Oncology SVP Finance Thomas Doyle Reports Disposal of Common Shares

Reuters
·
Nov 15, 2025

Kura Scores A Big Win As FDA Approves Its New Leukemia Pill

Benzinga_recent_news
·
Nov 15, 2025

Kura Oncology Up Over 16%, On Pace for Largest Percent Increase Since January 2024 -- Data Talk

Dow Jones
·
Nov 15, 2025

Kura Oncology Is Maintained at Outperform by Wedbush

Dow Jones
·
Nov 14, 2025

Kura Oncology Inc : UBS Raises Target Price to $16 From $14

THOMSON REUTERS
·
Nov 14, 2025

Kura Oncology price target raised to $30 from $29 at BofA

TIPRANKS
·
Nov 14, 2025

Kura Oncology (KURA) Gets a Buy from Bank of America Securities

TIPRANKS
·
Nov 14, 2025

UBS Sticks to Its Buy Rating for Kura Oncology (KURA)

TIPRANKS
·
Nov 14, 2025

Wedbush Lifts Price Target on Kura Oncology to $38 From $36, Keeps Outperform Rating

MT Newswires Live
·
Nov 14, 2025

U.S. RESEARCH ROUNDUP-Disney, Enanta Pharmaceuticals, Phillips 66

Reuters
·
Nov 14, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Broadwind, Verizon, APA

Reuters
·
Nov 14, 2025

Kura Oncology Exec Says U.S. Launch Price for One Month Supply of Once Daily Fixed Dose of Komzifti at $48,500

THOMSON REUTERS
·
Nov 14, 2025

Kura Oncology Exec Says Komzifti Delivery Expected Within Next Few Business Days

THOMSON REUTERS
·
Nov 14, 2025

Kura Oncology Exec Says Already in Dialog With FDA About Potential Steps Post Approval That Could Help Refine Labeling - Conf Call

THOMSON REUTERS
·
Nov 14, 2025

Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

GlobeNewswire
·
Nov 13, 2025

US FDA approves Kura Oncology's blood cancer therapy

Reuters
·
Nov 13, 2025

BRIEF-FDA Approves Ziftomenib For Relapsed Or Refractory Acute Myeloid Leukemia With A NPM1 Mutation

Reuters
·
Nov 13, 2025

FDA : Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukemia With a Npm1 Mutation

THOMSON REUTERS
·
Nov 13, 2025

FDA announces approval of Kura’s Komzifti for AML

TIPRANKS
·
Nov 13, 2025

Kura Oncology trading halted, news pending

TIPRANKS
·
Nov 13, 2025